Login




Aki

Preventing CRRT-induced hypophosphatemia by using a phosphate-containing CRRT solution in the setting of Regional Citrate Anticoagulation

Questo Abstract è stato accettato come Poster. Clicca qui per visualizzare

Razionale

Phosphate depletion is a known issue during CRRT, with an incidence of hypophosphatemia up to 80% when standard CRRT solutions are used. The aim was to evaluate the effects on serum phosphate and phosphorus supplementation needs of a regional citrate anticoagulation (RCA) protocol combining citrate with a phosphate-containing CRRT solution.

Casistica e Metodi

In heart surgery patients undergoing CRRT for acute kidney injury, we adopted RCA in CVVH or CVVHDF modality combining a commercially available citrate solution (18 mmol/l) with a phosphate-containing dialysate and/or replacement fluid (HCO3- 30 mmol/l, phosphate 1.2). Prescribed CRRT dose, corrected for pre-dilution, was at least 25 ml/kg/h with about 50-60% of dialysis dose given as phosphate-containing solution. Hypophosphatemia was defined as follows: mild (<0.81 mmol/l), moderate (<0.61 mmol/l) and severe (<0.32 mmol/l).

Risultati

Forty-eight patients were treated with RCA-CRRT for a total running time of 12502 hours. Two-hundred and nineteen circuits were used (mean filter life 57.1±41.7 hours, median 47, IQR 24-83). Acid-base status was adequately maintained without additional interventions on RCA-CRRT parameters [pH 7.43 (7.40-7.47), bicarbonate 25.3 mmol/l (23.8-26.6), BE 0.9 (-0.7 to 2.4); median (IQR)]. Serum phosphate was steadily maintained in a narrow range throughout RCA-CRRT days [1.2 mmol/l (0.97-1.45)]. At some times during CRRT, only 10 out of 48 patients (20.8%) received a low amount of phosphate supplementation (d-fructose-1,6-diphosphate 1.05±2.04 g/day) for mild (n=7) to moderate (n=3) hypophosphatemia. In particular, only 33 out of 513 serum phosphorus determinations met the criteria for mild (n = 24) to moderate (n = 9) hypophosphatemia. Severe hypophosphatemia was never observed.

Conclusioni

The use of a phosphate-containing CRRT solution, accounting for about 50-60% of CRRT dose in the setting of RCA-CVVH or RCA-CVVHDF, allowed to prevent CRRT-induced phosphate depletion in most of the patients, minimizing the need for phosphate supplementation and maintaining phosphorus levels in near normal range throughout CRRT days.

Valentina Pistolesi (1), Santo Morabito (1), Elio Vitaliano (2), Francesca Polistena (1), Laura Zeppilli (1), Maria Itala Sacco (1), Enrico Fiaccadori (3), Alessandro Pierucci (1)
(1 Nefrologia e Dialisi, Policlinico Umberto I, “Sapienza”, Università di Roma 2 Nefrologia e Dialisi, Ospedale S. Pertini, Roma 3 Dipartimento di Medicina Clinica e Sperimentale, Università di Parma )
Non sono presenti commenti
Figure
Realizzazione: TESISQUARE®

Per assistenza scrivere al Supporto Tecnico